Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: A preliminary study

Lisa A. Scherkenbach, Lisa D Coles, Ned Patterson, James C Cloyd, Linda E. Krach, Robert L. Kriel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Abrupt discontinuation of baclofen therapy is associated with a clinically serious withdrawal syndrome. Current treatment modalities are often ineffective. Intravenous (IV) baclofen is a potential method for preventing or treating baclofen withdrawal syndrome. Objectives To complete a preliminary study of IV baclofen in dogs. Methods Single bolus IV doses (0.5, 2 and 3 mg/kg) as well as multiple dose regimens were evaluated. Sedation and clinical tolerability was assessed by modified Glasgow Coma Scale and Discomfort and Behaviour Scale. Key findings Baclofen concentration-time profiles following single IV boluses were best fit by a two-compartment model which was used to predict plasma concentrations for the multiple dose regimens. The mean distribution and elimination half-lives were 11 min and 222 min, respectively. Maximum clinical effect did not occur until approximately 120 min. The discomfort score increased proportionately with increased single IV bolus doses. Multiple dose regimens resulted in greater than proportionate discomfort scores based on total dose and were generally not as well tolerated. Conclusions If projected for human use, our data suggests that initial IV baclofen doses will need to be reduced by approximately one-third of the usual oral dose, and clinicians should observe patients for several hours before administering subsequent doses.

Original languageEnglish (US)
Pages (from-to)935-942
Number of pages8
JournalJournal of Pharmacy and Pharmacology
Volume66
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

Baclofen
Pharmacokinetics
Dogs
Glasgow Coma Scale
Therapeutics

Keywords

  • baclofen
  • baclofen pharmacokinetics and disposition
  • baclofen withdrawal
  • intravenous baclofen

Cite this

Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs : A preliminary study. / Scherkenbach, Lisa A.; Coles, Lisa D; Patterson, Ned; Cloyd, James C; Krach, Linda E.; Kriel, Robert L.

In: Journal of Pharmacy and Pharmacology, Vol. 66, No. 7, 01.01.2014, p. 935-942.

Research output: Contribution to journalArticle

@article{bd20adbbaddc420397834e6946ea2cde,
title = "Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: A preliminary study",
abstract = "Abrupt discontinuation of baclofen therapy is associated with a clinically serious withdrawal syndrome. Current treatment modalities are often ineffective. Intravenous (IV) baclofen is a potential method for preventing or treating baclofen withdrawal syndrome. Objectives To complete a preliminary study of IV baclofen in dogs. Methods Single bolus IV doses (0.5, 2 and 3 mg/kg) as well as multiple dose regimens were evaluated. Sedation and clinical tolerability was assessed by modified Glasgow Coma Scale and Discomfort and Behaviour Scale. Key findings Baclofen concentration-time profiles following single IV boluses were best fit by a two-compartment model which was used to predict plasma concentrations for the multiple dose regimens. The mean distribution and elimination half-lives were 11 min and 222 min, respectively. Maximum clinical effect did not occur until approximately 120 min. The discomfort score increased proportionately with increased single IV bolus doses. Multiple dose regimens resulted in greater than proportionate discomfort scores based on total dose and were generally not as well tolerated. Conclusions If projected for human use, our data suggests that initial IV baclofen doses will need to be reduced by approximately one-third of the usual oral dose, and clinicians should observe patients for several hours before administering subsequent doses.",
keywords = "baclofen, baclofen pharmacokinetics and disposition, baclofen withdrawal, intravenous baclofen",
author = "Scherkenbach, {Lisa A.} and Coles, {Lisa D} and Ned Patterson and Cloyd, {James C} and Krach, {Linda E.} and Kriel, {Robert L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/jphp.12221",
language = "English (US)",
volume = "66",
pages = "935--942",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs

T2 - A preliminary study

AU - Scherkenbach, Lisa A.

AU - Coles, Lisa D

AU - Patterson, Ned

AU - Cloyd, James C

AU - Krach, Linda E.

AU - Kriel, Robert L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Abrupt discontinuation of baclofen therapy is associated with a clinically serious withdrawal syndrome. Current treatment modalities are often ineffective. Intravenous (IV) baclofen is a potential method for preventing or treating baclofen withdrawal syndrome. Objectives To complete a preliminary study of IV baclofen in dogs. Methods Single bolus IV doses (0.5, 2 and 3 mg/kg) as well as multiple dose regimens were evaluated. Sedation and clinical tolerability was assessed by modified Glasgow Coma Scale and Discomfort and Behaviour Scale. Key findings Baclofen concentration-time profiles following single IV boluses were best fit by a two-compartment model which was used to predict plasma concentrations for the multiple dose regimens. The mean distribution and elimination half-lives were 11 min and 222 min, respectively. Maximum clinical effect did not occur until approximately 120 min. The discomfort score increased proportionately with increased single IV bolus doses. Multiple dose regimens resulted in greater than proportionate discomfort scores based on total dose and were generally not as well tolerated. Conclusions If projected for human use, our data suggests that initial IV baclofen doses will need to be reduced by approximately one-third of the usual oral dose, and clinicians should observe patients for several hours before administering subsequent doses.

AB - Abrupt discontinuation of baclofen therapy is associated with a clinically serious withdrawal syndrome. Current treatment modalities are often ineffective. Intravenous (IV) baclofen is a potential method for preventing or treating baclofen withdrawal syndrome. Objectives To complete a preliminary study of IV baclofen in dogs. Methods Single bolus IV doses (0.5, 2 and 3 mg/kg) as well as multiple dose regimens were evaluated. Sedation and clinical tolerability was assessed by modified Glasgow Coma Scale and Discomfort and Behaviour Scale. Key findings Baclofen concentration-time profiles following single IV boluses were best fit by a two-compartment model which was used to predict plasma concentrations for the multiple dose regimens. The mean distribution and elimination half-lives were 11 min and 222 min, respectively. Maximum clinical effect did not occur until approximately 120 min. The discomfort score increased proportionately with increased single IV bolus doses. Multiple dose regimens resulted in greater than proportionate discomfort scores based on total dose and were generally not as well tolerated. Conclusions If projected for human use, our data suggests that initial IV baclofen doses will need to be reduced by approximately one-third of the usual oral dose, and clinicians should observe patients for several hours before administering subsequent doses.

KW - baclofen

KW - baclofen pharmacokinetics and disposition

KW - baclofen withdrawal

KW - intravenous baclofen

UR - http://www.scopus.com/inward/record.url?scp=84902551177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902551177&partnerID=8YFLogxK

U2 - 10.1111/jphp.12221

DO - 10.1111/jphp.12221

M3 - Article

C2 - 24697865

AN - SCOPUS:84902551177

VL - 66

SP - 935

EP - 942

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 7

ER -